Prospective Cohort for Adult Hemophagocytosis
A Prospective Cohort for Subjects With Adult Hemophagocytic Lymphohistiocytosis Like Syndrome
1 other identifier
observational
81
1 country
1
Brief Summary
This prospective study enrolls subjects who have clinical and laboratory manifestations related with hemophagocytic lymphohistiocytosis. The purpose of the study is to evaluate clinical and biological features of adult hemophagocytic lymphohistiocytosis. The enrolled subjects into this study will be evaluated according to the HLH (hemophagocytic lymphohistiocytosis)criteria and treated with systemic immunosuppressive therapy or chemotherapy. All subjects will be regularly monitored by physicians participating in this study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2017
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedFirst Submitted
Initial submission to the registry
April 12, 2017
CompletedFirst Posted
Study publicly available on registry
April 17, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2028
April 24, 2026
April 1, 2026
12 years
April 12, 2017
April 23, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Response
Response to steroids and etoposide
28 days after the 1st treatment
Secondary Outcomes (2)
Progression-free survival
3 years
Overall survival
3 years
Study Arms (1)
Hemophagocytosis
Subjects should fulfill the following criteria 1. Subjects should have at least one of the following problems 1. Presence of hemophagocytosis in tissue or bone marrow 2. Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria 2. Age \> 18 years 3. Written informed consents Subjects receive steroids and etoposide
Interventions
Eligibility Criteria
Subjects who have clinical and laboratory manifestations related with hemophagocytic lymphohistiocytosis.
You may qualify if:
- Subjects should fulfill the following criteria
- Subjects should have at least one of the following problems
- Presence of hemophagocytosis in tissue or bone marrow
- Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria
- Age \> 18 years
- Written informed consents
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Samsung Medical Center
Seoul, 135-710, South Korea
Related Publications (1)
Yoon SE, Eun Y, Huh K, Chung CR, Yoo IY, Cho J, Cho D, Ko YH, Park S, Kim WS, Kim SJ. A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study. Ann Hematol. 2020 Sep;99(9):2095-2104. doi: 10.1007/s00277-020-04083-6. Epub 2020 May 21.
PMID: 32440790DERIVED
Biospecimen
1. Serum sample collection will be done as follows: Baseline, 4 weeks after treatment, Relapse or progression 2. Germline DNA collection from peripheral blood will be done at the enrollment
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Seok Jin Kim, MD, PhD
Samsung Medical Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 12, 2017
First Posted
April 17, 2017
Study Start
January 1, 2017
Primary Completion (Estimated)
December 31, 2028
Study Completion (Estimated)
December 31, 2028
Last Updated
April 24, 2026
Record last verified: 2026-04